. 2022 Apr 10;279(11):5191–5198. doi: 10.1007/s00405-022-07368-w

Table 4.

Seven patients identified as having autoimmune co-morbidities

Patient number	Autoimmune co-morbidity	Number of procedures	Duration of symptom control per procedure (months)				Longest asymptomatic period (months)
Patient number	Autoimmune co-morbidity	Number of procedures	1st	2nd	3rd	4th	Longest asymptomatic period (months)
5	Pernicious Anaemia	1	11				11
12	Polychondritis	2	14	2			14
13	Alopecia	1	21				21
17	Ankylosing Spondylitis	1	15				15
20	Coeliac	2	12	64			64
21	Psoriasis	2	16	1			16
23	Polyarthritis	3	33	32	12		33

Despite being a predictor of response, the presence of an autoimmune co-morbidity did not lead to a difference in the duration of response to IT dexamethasone per procedure or the longest asymptomatic period